WO2012165815A3 - 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 - Google Patents

종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 Download PDF

Info

Publication number
WO2012165815A3
WO2012165815A3 PCT/KR2012/004162 KR2012004162W WO2012165815A3 WO 2012165815 A3 WO2012165815 A3 WO 2012165815A3 KR 2012004162 W KR2012004162 W KR 2012004162W WO 2012165815 A3 WO2012165815 A3 WO 2012165815A3
Authority
WO
WIPO (PCT)
Prior art keywords
nano
tumor tissue
vehicle
cancer vaccine
same
Prior art date
Application number
PCT/KR2012/004162
Other languages
English (en)
French (fr)
Other versions
WO2012165815A2 (ko
Inventor
고용성
김윤근
이은영
장수철
Original Assignee
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포항공과대학교 산학협력단 filed Critical 포항공과대학교 산학협력단
Priority to US13/823,315 priority Critical patent/US9220763B2/en
Priority to CN2012800037132A priority patent/CN103221034A/zh
Priority to EP12793342.2A priority patent/EP2617413A4/en
Priority to JP2013534840A priority patent/JP2013543519A/ja
Publication of WO2012165815A2 publication Critical patent/WO2012165815A2/ko
Publication of WO2012165815A3 publication Critical patent/WO2012165815A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 암 백신에 관한 것으로, 구체적으로 종양 조직에서 유래한 나노소포체를 포함하는 암 치료용 약학적 조성물 및 상기 종양 조직 유래 나노 소포체를 이용하여 암을 치료하는 방법 등에 관한 것이다. 본 발명에 따른 종양 조직 유래 나노소포체 항원은 세포밖 소포체와 유사한 속성을 지니면서도 높은 수득률을 나타내고, 아울러 다양한 변형이 가능함으로써 암 치료백신 개발에 매우 유용할 것으로 기대된다.
PCT/KR2012/004162 2011-05-27 2012-05-25 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 WO2012165815A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/823,315 US9220763B2 (en) 2011-05-27 2012-05-25 Nano-vehicle derived from tumor tissue, and cancer vaccine using same
CN2012800037132A CN103221034A (zh) 2011-05-27 2012-05-25 来自肿瘤组织的纳米囊泡及使用该纳米囊泡的癌症疫苗
EP12793342.2A EP2617413A4 (en) 2011-05-27 2012-05-25 NANIUM DERIVED FROM A TUMOR TISSUE AND CANCER VACCINE THEREFOR
JP2013534840A JP2013543519A (ja) 2011-05-27 2012-05-25 腫瘍組織に由来するナノベシクル、及びこれを用いた癌ワクチン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110050854A KR20120132183A (ko) 2011-05-27 2011-05-27 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
KR10-2011-0050854 2011-05-27

Publications (2)

Publication Number Publication Date
WO2012165815A2 WO2012165815A2 (ko) 2012-12-06
WO2012165815A3 true WO2012165815A3 (ko) 2013-02-07

Family

ID=47260042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004162 WO2012165815A2 (ko) 2011-05-27 2012-05-25 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신

Country Status (6)

Country Link
US (1) US9220763B2 (ko)
EP (1) EP2617413A4 (ko)
JP (1) JP2013543519A (ko)
KR (1) KR20120132183A (ko)
CN (1) CN103221034A (ko)
WO (1) WO2012165815A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357538B2 (en) * 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
KR101473557B1 (ko) 2013-03-29 2014-12-24 포항공과대학교 산학협력단 원심력을 이용한 세포유래 인공 마이크로베시클 제조 장치
KR101745455B1 (ko) * 2015-03-24 2017-06-09 포항공과대학교 산학협력단 수용액 이상계를 이용한 세포 밖 소포체의 다단계 정제방법
KR101761680B1 (ko) * 2015-03-31 2017-08-23 포항공과대학교 산학협력단 수용액 이상계를 이용한 세포 밖 소포체의 분리방법
KR101833502B1 (ko) * 2016-12-16 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 위암 진단방법
CN108295250B (zh) * 2017-01-12 2023-07-21 湖北盛齐安生物科技股份有限公司 一种口服肿瘤疫苗及其用途
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
CN108324958B (zh) * 2018-05-17 2021-09-24 陕西师范大学 一种紫红素18-脂质体纳米囊泡的制备方法以及在制备用于治疗肿瘤药物中的应用
CN110628719B (zh) * 2019-09-23 2021-08-24 山东省医学科学院基础医学研究所 一种诱导细胞快速产生囊泡的方法及其应用
CN110974976A (zh) * 2019-12-16 2020-04-10 天津市第三中心医院 羧甲基壳聚糖修饰载药囊泡及其制备与应用
CN111991565A (zh) * 2019-12-17 2020-11-27 河南牧业经济学院 促吞噬肽修饰阿魏酸生物可降解纳米囊泡的制备方法
CN113332312B (zh) * 2021-02-01 2023-02-24 浙江大学医学院附属邵逸夫医院 一种基于物理整粒的自成形血小板纳米囊泡及其制备方法
WO2022245144A1 (ko) * 2021-05-20 2022-11-24 주식회사 뉴메이스 고압 유체 분산 방법을 이용한 세포 유래 나노소포체의 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075315A1 (en) * 2004-06-02 2010-03-25 Zbigniew Pietrzkowski Microvesicle-Based Compositions and Methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
WO1999058645A1 (en) * 1998-05-11 1999-11-18 I.N.S.E.R.M. (Institut National de la Santé et de la Recherche Médicale) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
KR100796220B1 (ko) 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
JP2005281266A (ja) 2004-03-31 2005-10-13 Takeshi Kobayashi 温熱細胞ワクチンとサイトカインを含む医薬用組成物およびその調製方法
CA2609260A1 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
DE102008033175A1 (de) 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
EP2355797A1 (en) * 2008-10-21 2011-08-17 Domantis Limited Composition for targeting dendritic cells
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
WO2012002759A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세포의 원형질체에서 유래한 마이크로베시클 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075315A1 (en) * 2004-06-02 2010-03-25 Zbigniew Pietrzkowski Microvesicle-Based Compositions and Methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
K. AL-NEDAWI ET AL.: "Microvescicles: Messengers and mediators of tumor progression", CELL CYCLE, vol. 8, no. 13, 1 July 2009 (2009-07-01), pages 2014 - 2018, XP008161991 *
M. BAJ-KRZYWORZEKA ET AL.: "Tumor-derived microvesicles carry several surface determinants and mRNA of tumor cells and transfer some of these determinants to monocytes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 55, 2006, pages 808 - 818, XP019333260 *
M. SZAJNIK ET AL.: "Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T-cells (Treg)", PLOS ONE, vol. 5, no. 7, July 2010 (2010-07-01), pages 1 - 13, XP002697141 *
M. WYSOCZYNSKI ET AL.: "Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors", INTERNATIONAL JOURNAL OF CANCER, vol. 125, no. 7, 1 October 2009 (2009-10-01), pages 1595 - 1603, XP002592725 *
R. VALENTI ET AL.: "Tumor-released microvesicles as vehicles of immunosuppression", CANCER RESEARCH, vol. 67, no. 7, 1 April 2007 (2007-04-01), pages 2912 - 2915, XP002523308 *
X. LI ET AL.: "Nanovesicular vaccines: exosomes", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMANTALIS, vol. 53, no. 4, 2005, pages 329 - 335, XP009149577 *

Also Published As

Publication number Publication date
EP2617413A2 (en) 2013-07-24
US20130177595A1 (en) 2013-07-11
KR20120132183A (ko) 2012-12-05
WO2012165815A2 (ko) 2012-12-06
JP2013543519A (ja) 2013-12-05
US9220763B2 (en) 2015-12-29
CN103221034A (zh) 2013-07-24
EP2617413A4 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
WO2012165815A3 (ko) 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
WO2012159754A3 (en) Individualized vaccines for cancer
PH12017500864A1 (en) Anti-notch1 antibodies
WO2013068563A3 (en) Antibody molecules having specificity for human ox40
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
WO2013006547A3 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
MX2013009362A (es) Anticuerpo contra el csf-1r.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
IN2014DN06164A (ko)
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793342

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13823315

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012793342

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013534840

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE